ARISTOTELES Applying ARtificial Intelligence to Define clinical trajectorieS for personalized predicTiOn and early deTEctiOn of comorbidiTy and muLtimorbidiTy pattErnS
- Coordinator
- Universita Degli Studi Di Modena E Reggio Emilia, Italy
- Runs
- 1 November 2023 to 31 October 2028
- Status
- Running
- EU funding
- €4.1m
- Total cost
- €4.1m
- Partners
- 18 organisations in 10 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101080189
What the project is doing
In the project's own words, from its summary on CORDIS.
The ARISTOTELES project aims to build a multinational harmonized data platform to develop and implement novel artificial intelligence (AI) approaches for management of complex diseases, where progression and manifestations of comorbidities are via multiple interacting pathways. We aim to apply our novel approach to a population of great need due to atrial fibrillation (AF), but our outputs can be extended to other complex diseases with multimorbidity.
By integrating AIs into clinical practice, our platform will form a backbone for acceptable, responsible, and respectful uses of patient/participant data to develop and validate novel trustworthy AI tools for more personalized risk assessment and management. This represents a paradigm shift in AF treatment, moving from a focus on individual risk factors and selected outcomes (eg. stroke) to a holistic approach, underpinning timely diagnostic and therapeutic interventions to reduce disease progression, disability, hospitalizations and mortality, as well as improve patient adherence to lifestyle modifications, medications, and other treatment regimens.
ARISTOTELES will be delivered through 8 inter-linking work-packages (WPs): WP1 is study management/coordination. WP2 provides the ethical/legal requirements for the development of a trustworthy AI. WP3 addresses stakeholder understanding of AI, needs assessment, and engagement in all the phases of the AI development. In WP4, granular data on genotype and phenotype characteristics, are harmonized from different datasets into a common platform.
In WP5, AI algorithms/tools are developed and connected to an interactive output interface for patients and clinicians. In WP6, we test the AI tool developed in WP5 in a clinical trial simulation (in silico trial). In WP7 a multicenter randomized trial runs across multiple countries including both primary care and secondary care. WP7 and WP8 drive the clinical implementation and dissemination of results.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Degli Studi Di Modena E Reggio Emilia | Modena | Italy | Coordinator |
| Moverim SRL | Bruxelles / Brussel | Belgium | Participant |
| Aalborg Universitet | Aalborg | Denmark | Participant |
| Panepistimio Kritis | Rethimno | Greece | Participant |
| Idoven 1903 SL | Madrid | Spain | Associatedpartner |
| Iotic Solutions SL | Murcia | Spain | Participant |
| Universidad De Murcia | Murcia | Spain | Participant |
| Gers SAS | Boulogne-Billancourt | France | Participant |
| Datariver SRL | Modena | Italy | Associatedpartner |
| Hcf Fondazione Anmco per Il Tuo Cuore Ets | Firenze | Italy | Participant |
| Universitetet I Oslo | Oslo | Norway | Participant |
| Universidade De Coimbra | Coimbra | Portugal | Participant |
| Universitatea De Medicina Si Farmacie Carol Davila Din Bucuresti | Bucuresti | Romania | Participant |
| Aimes Management Services Limited | Liverpool | United Kingdom | Associatedpartner |
| Liverpool John Moores University | Liverpool | United Kingdom | Associatedpartner |
| The University of Liverpool | Liverpool | United Kingdom | Associatedpartner |
| The University of Manchester | Manchester | United Kingdom | Associatedpartner |
| University College London | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI